Tolerability and Safety of Primaquine in Papua New Guinean Children 1 to 10 Years of Age

View/ Open
File version
Version of Record (VoR)
Author(s)
Beteula, Inoni
Bassat, Quique
Kiniboro, Benson
Robinson, Leanne J.
Rosanas-Urgell, Anna
Stanisic, Danielle
Siba, Peter M.
Alonso, Pedro L.
Mueller, Ivo
Griffith University Author(s)
Year published
2012
Metadata
Show full item recordAbstract
Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.Primaquine is currently the only drug available for radical cure of Plasmodium vivax and P. ovale liver infection stages, but limited safety data exist for children <10 years of age. Detailed daily assessments of side effects in glucose-6-phosphate dehydrogenase (G6PD)-normal children treated with 14 days of primaquine plus chloroquine (3 days; n = 252) or artesunate (7 days; n = 141) (0.5 mg/kg of body weight) showed that both treatments are well tolerated, do not lead to reductions in hemoglobin levels, and can thus safely be used in children 1 to 10 years of age.
View less >
View less >
Journal Title
Antimicrobial agents and Chemotherapy
Volume
56
Issue
4
Copyright Statement
© 2012 American Society for Microbiology. The attached file is reproduced here in accordance with the copyright policy of the publisher. Please refer to the journal's website for access to the definitive, published version.
Subject
Microbiology
Medical microbiology
Pharmacology and pharmaceutical sciences